DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ortho (Ethinyl Estradiol) - Summary

 



ORTHO SUMMARY

ORTHO EVRA® is a combination transdermal contraceptive patch with a contact surface area of 20 cm2. It contains 6.00 mg norelgestromin and 0.75 mg ethinyl estradiol (EE), and releases 150 micrograms of norelgestromin and 20 micrograms of EE to the bloodstream per 24 hours.

ORTHO EVRA® is indicated for the prevention of pregnancy.
See all indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Ortho (Ethinyl Estradiol)

American Academy Of Orthopaedic Surgeons Wins Prestigious CLIO Award
Source: Bones / Orthopaedics News From Medical News Today [2009.11.17]
The first-ever CLIO Healthcare Award - a new category of the internationally distinguished CLIO Awards -- has awarded the American Academy of Orthopaedic Surgeons (AAOS), a Silver CLIO for the Academy's year-long campaign "75 Years of Orthopaedic History.

American Association Of Orthopaedic Surgeons, Nineteen Other Surgical Groups Call For Changes To Senate Health Legislation
Source: Bones / Orthopaedics News From Medical News Today [2009.11.06]
The American Association of Orthopaedic Surgeons (AAOS) joined nineteen other surgical organizations, led by the American College of Surgeons, to send a letter to the U.S. Senate today reiterating they are prepared to oppose the Senate's health care reform bill due to its threat to patients' access to specialty care and its potential to harm quality care. This coalition represents over 240,000 surgeons and anesthesiologists.

BioMimetic Therapeutics Receives First Orthopedic Marketing Approval For Augment™ Bone Graft
Source: Bones / Orthopaedics News From Medical News Today [2009.11.04]
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) announced today that it has received approval from Health Canada to begin the marketing of its lead orthopedic product, Augment™ Bone Graft, as an alternative to the use of autograft in midfoot, hindfoot and ankle fusion indications in Canada. "After rigorous pre-clinical and clinical evaluation of the product, BioMimetic is now ready to introduce this novel, implantable biologic to the marketplace," commented Dr. Samuel E.

Orthostatic Hypotension
Source: MedicineNet Addison Disease Specialty [2009.06.11]
Title: Orthostatic Hypotension
Category: Diseases and Conditions
Created: 6/11/2009
Last Editorial Review: 6/11/2009

Orthopox
Source: MedicineNet Monkeypox Specialty [2003.06.16]
Title: Orthopox
Category: Medical Dictionary
Created: 6/8/2003
Last Editorial Review: 6/16/2003

more news >>

Published Studies Related to Ortho (Ethinyl Estradiol)

Shear bond strength of orthodontic brackets bonded with different self-etching adhesives. [2009.09]
INTRODUCTION: The purpose of this study was to compare the shear bond strength (SBS) of orthodontic brackets bonded with 4 self-etching adhesives... CONCLUSIONS: The 4 self-etching adhesives yielded SBS values higher than the bond strength (5.9 to 7.8 MPa) suggested for routine clinical treatment, indicating that orthodontic brackets can be successfully bonded with any of these self-etching adhesives.

Effect of fluoride-releasing light-cured resin on shear bond strength of orthodontic brackets. [2009.01]
INTRODUCTION: The aim of this study was to analyze the effect of an enamel-protective resin on the shear bond strength (SBS) of orthodontic brackets bonded with self-etching primer... CONCLUSIONS: The application of enamel-protective resin did not affect the bond strength of orthodontic brackets to enamel with self-etching primer systems.

Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. [2008.10]
OBJECTIVE: To assess the efficacy of the combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol (3-mg drospirenone/20-microgram ethinyl estradiol) administered as 24 consecutive days of active treatment after a 4-day hormone-free interval (24/4 regimen) compared with placebo for the treatment of moderate acne vulgaris... CONCLUSION: The low-dose combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol administered in a 24/4 regimen significantly reduced acne lesion counts more effectively than placebo and demonstrated greater improvement in the Investigator Static Global Assessment rating of acne. The safety profile was consistent with low-dose combined oral contraceptive use.

The efficacy of a plasma arc light in orthodontic bonding: a randomized controlled clinical trial. [2008.09]
OBJECTIVE: To evaluate the clinical performance of a plasma arc light (Ortho LITE, 3M Unitek, Monrovia, CA, USA) against a conventional tungsten-quartz halogen curing light (Visilux 2, 3M Unitek, Monrovia, CA, USA) for direct orthodontic bonding... CONCLUSION: The plasma arc light is a viable clinical alternative to the conventional halogen curing light with benefits for both the clinician and patient due to reduced bonding times.

Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. [2008.09]
BACKGROUND: In postmenopausal women, declining estrogen levels are associated with a variety of skin changes, many of which are reportedly improved by estrogen supplementation. OBJECTIVE: A study was conducted to assess the effects of continuous combined norethindrone acetate (NA) and ethinyl estradiol (EE) in the control of mild to moderate age-related skin changes in postmenopausal women... CONCLUSION: Low-dose hormone therapy for 48 weeks in postmenopausal women did not significantly alter mild to moderate age-related facial skin changes.

more studies >>

Clinical Trials Related to Ortho (Ethinyl Estradiol)

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada) [Recruiting]
The objective of the study is to compare the oral contraceptive (OC) SH T00658ID over Ortho Tri-Cyclen Lo administered for 13 cycles to healthy female volunteers between 18 and 50 years of age who request oral contraceptive protection. Subjects on a LNG, NGM, or norethindrone/norethindrone acetate containing oral contraceptive in a 21-day regimen suffering from hormone withdrawal-associated symptoms such of pelvic pain or headache or both, and willing to continue OC use but to switch to SH T00658ID or Ortho Tri-Cyclen Lo.

Drug Interaction - Oral Contraceptive [Completed]
The purpose of this study is to administer a combined oral contraceptive containing ethinyl estradiol and norgestimate with the HIV treatment of efavirenz to healthy females in order to assess if the concentrations of the oral contraceptives change. The safety of this treatment regimen will also be studied.

A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRAŽ (a Transdermal Contraceptive Patch) [Completed]

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-CyclenŽ in Healthy Female Subjects [Not yet recruiting]

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women [Active, not recruiting]
The purpose of this study is to examine the drug interactions between a protease inhibitor (PI)-based regimen including lopinavir/ritonavir (LPV/r) and two forms of contraceptive medications in HIV infected women.

more trials >>

Page last updated: 2009-11-17

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009